{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T01:06:52Z","timestamp":1789175212408,"version":"build-2803163510"},"reference-count":96,"publisher":"Wiley","issue":"8","license":[{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2026,7,12]],"date-time":"2026-07-12T00:00:00Z","timestamp":1783814400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100019978","name":"Shanghai Pudong New Area Health Commission","doi-asserted-by":"publisher","award":["2026\u2010PWDL\u201012"],"award-info":[{"award-number":["2026\u2010PWDL\u201012"]}],"id":[{"id":"10.13039\/501100019978","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82174186"],"award-info":[{"award-number":["82174186"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Liver International"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Compensated cirrhosis due to metabolic dysfunction\u2010associated steatohepatitis (MASH) represents a major unmet need in hepatology, with no approved treatment to date. Compared with non\u2010cirrhotic MASH, compensated cirrhosis is characterized by concurrent metabolic dysfunction, persistent inflammation, stabilized fibrosis and portal hypertension, making therapeutic development substantially more challenging. In recent years, several agents initially developed for non\u2010cirrhotic disease have advanced into compensated MASH\u2010related cirrhosis, including fibroblast growth factor 21 analogues, glucagon\u2010like peptide\u20101 receptor\/glucagon receptor dual agonists, thyroid hormone receptor\u2010beta agonists and other antifibrotic approaches. Among these, fibroblast growth factor 21 analogues have shown the most encouraging efficacy signals. However, most candidates have not demonstrated clear histological or clinical benefit in this population. The predominance of negative trials suggests that limited progress reflects not only insufficient drug efficacy, but also disease complexity, marked patient heterogeneity and limitations of current endpoint frameworks. This review summarizes recent progress in drug development for compensated MASH\u2010related cirrhosis, evaluates the efficacy and safety of major investigational agents, and discusses key barriers to development, including endpoint limitations, patient stratification and trial design. It also outlines future directions, including precision stratification, composite endpoints, noninvasive assessment tools, combination strategies and earlier screening and intervention.<\/jats:p>","DOI":"10.1111\/liv.70784","type":"journal-article","created":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T04:49:55Z","timestamp":1783918195000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Drug Development for\n                    <scp>MASH<\/scp>\n                    \u2010Related Compensated Cirrhosis: Past, Present and Future"],"prefix":"10.1111","volume":"46","author":[{"given":"Ren\u2010Qiang","family":"Zeng","sequence":"first","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi\u2010Xuan","family":"Shao","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-6487-7675","authenticated-orcid":false,"given":"Ru\u2010Tao","family":"Lin","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu\u2010Ting","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Clinical Laboratory Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qin\u2010Mei","family":"Sun","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"},{"name":"Institute of Interdisciplinary Medicine Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Xin","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"},{"name":"Key Laboratory of Liver and Kidney Diseases, Ministry of Education Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ping","family":"Liu","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"},{"name":"Key Laboratory of Liver and Kidney Diseases, Ministry of Education Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8618-6402","authenticated-orcid":false,"given":"Jian\u2010Gao","family":"Fan","sequence":"additional","affiliation":[{"name":"Center for Fatty Liver, Department of Gastroenterology Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine  Shanghai China"},{"name":"Shanghai Key Laboratory of Pediatric Gastroenterology and Nutrition  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9127-7002","authenticated-orcid":false,"given":"Yi\u2010Yang","family":"Hu","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"},{"name":"Clinical Research Center Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4641-1636","authenticated-orcid":false,"given":"Qin","family":"Feng","sequence":"additional","affiliation":[{"name":"Institute of Liver Diseases Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine  Shanghai China"},{"name":"Key Laboratory of Liver and Kidney Diseases, Ministry of Education Shanghai University of Traditional Chinese Medicine  Shanghai China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,7,12]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2022.04.014"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.156043"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2020.100057"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)01073\u20106"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2022.100563"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502242"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(25)00309-5"},{"key":"e_1_2_11_10_1","unstructured":"ClinicalTrials.gov \u201cA Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis due to NASH\/MASH \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT06528314."},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.123.001618"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2304286"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(22)00347\u20108"},{"key":"e_1_2_11_14_1","unstructured":"ClinicalTrials.gov \u201cA Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis due to MASH \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT06419374."},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/s42255\u2010024\u201000986\u20100"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0168-8278(25)00311-3"},{"key":"e_1_2_11_18_1","unstructured":"ClinicalTrials.gov \u201cA Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well\u2010Compensated NASH Cirrhosis (MAESTRO\u2010NASH\u2010OUTCOMES) \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT05500222."},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2401755"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.06.003"},{"key":"e_1_2_11_21_1","unstructured":"ClinicalTrials.gov \u201cLIVERAGE\u2014Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH\/MASH Who Have Cirrhosis \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT06632457."},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0511167103"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2010.09.020"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0075361"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.296"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000001774"},{"key":"e_1_2_11_27_1","unstructured":"R.Vuppalanchi N.Alkhouri K.Jamil S.Zuckerman andN.Chalasani \u201cBelapectin Reduces Liver Stiffness Progression and Prevents Varices at 18 Months in MASH Cirrhosis: Results From the NAVIGATE Trial. Presented at: The Liver Meeting. Washington DC USA \u201d(2025)."},{"key":"e_1_2_11_28_1","unstructured":"E.Lawitz M.Noureddin N.Chalasani et\u00a0al. \u201cBelapectin Maintains a Favorable Trend in Reducing Variceal Development Over 36 Months in MASH Cirrhosis: Results From the NAVIGATE Trial. Presented at: The Liver Meeting. Washington DC USA \u201d(2025)."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468\u20101253(25)00067\u20106"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(25)02276\u20107"},{"key":"e_1_2_11_31_1","doi-asserted-by":"crossref","unstructured":"M.Noureddin K. V.Kowdley K.Kutch B.Jeglinski M. J.Koziel andR.Loomba \u201cOnce\u2010Monthly Efimosfermin Alfa for up to 48\u2009Weeks in Metabolic Dysfunction\u2010Associated Steatohepatitis With F2\/F3 Fibrosis: Results From a Phase 2 Open\u2010Label Extension Study. Presented at: The Liver Meeting. Washington DC USA \u201d(2025).","DOI":"10.1016\/S0016-5085(25)04659-1"},{"key":"e_1_2_11_32_1","unstructured":"ClinicalTrials.gov \u201cA Study of Efimosfermin Alfa in Participants With Biopsy\u2010Confirmed Cirrhosis (Compensated) due to MASH \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT06920043."},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.05.013"},{"key":"e_1_2_11_34_1","unstructured":"ClinicalTrials.gov \u201cA Clinical Study of Efinopegdutide in People With Compensated Cirrhosis due to Steatohepatitis (MK\u20106024\u2010017) \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT06465186."},{"key":"e_1_2_11_35_1","unstructured":"ClinicalTrials.gov \u201cStudy Evaluating the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis due to Nonalcoholic Steatohepatitis \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT03439254."},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.29514"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2020.02.027"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(18)31785\u20109"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.04.012"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000607"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413258"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(23)00068-7"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102016\u2010312473"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.006"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109\u2010018\u20101642\u20109"},{"key":"e_1_2_11_46_1","unstructured":"ClinicalTrials.gov \u201cA Study of IDN\u20106556 in Cirrhotic Subjects With Portal Hypertension \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT02230683."},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2019.12.010"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmed.2006.12.001"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/labinvest.3700271"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32181"},{"key":"e_1_2_11_51_1","unstructured":"ClinicalTrials.gov \u201cSafety and Effectiveness of BMS\u2010986263 in Adults With Compensated Cirrhosis (Liver Disease) From Nonalcoholic Steatohepatitis (NASH) \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT04267393."},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abp8309"},{"key":"e_1_2_11_53_1","unstructured":"ClinicalTrials.gov \u201cA Study to Test How Well BI 770371 Is Tolerated by People With Cirrhosis Caused by a Liver Disease Called MASH \u201d(2026) https:\/\/clinicaltrials.gov\/study\/NCT06675929."},{"key":"e_1_2_11_54_1","volume-title":"OSE Immunotherapeutics Accelerates Strategic Refocusing to Advance Late\u2010Stage Value Drivers Lusvertikimab and Tedopi","author":"OSE Immunotherapeutics","year":"2026"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31205"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2018.07.027"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31622"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003172\u20107"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.04.003"},{"key":"e_1_2_11_60_1","unstructured":"N.Alkhouri K. V.Kowdley E.Lawitz A. J.Sanyal R.Vuppalanchi andA.Jakiche A Randomized Placebo\u2010Controlled Phase 2 Study of the Safety and Efficacy of Combination Treatment With Semaglutide Cilofexor and Firsocostat in Patients With Compensated Cirrhosis due to Metabolic Dysfunction\u2010Associated Steatohepatitis (WAYFIND). Presented at: The Liver Meeting. Washington DC USA(2025)."},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.70565"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.034"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0904187106"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2014.07.044"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2015.11.012"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28523"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2013.04.005"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2011.11.062"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2014.07.012"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2014\u20102001"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmet.2015.12.008"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010023\u201000846\u20104"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.mam.2023.101191"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.03.038"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2016.07.009"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms24119671"},{"key":"e_1_2_11_77_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010020\u201000372\u20107"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.12.022"},{"key":"e_1_2_11_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-024-00955-8"},{"key":"e_1_2_11_80_1","unstructured":"U.S. Food and Drug Administration \u201cNonalcoholic Steatohepatitis With Compensated Cirrhosis: Developing Drugs for Treatment: Guidance for Industry \u201d(2019) https:\/\/www.fda.gov\/media\/127738\/download."},{"key":"e_1_2_11_81_1","unstructured":"European Medicines Agency \u201cDraft Reflection Paper on Regulatory Requirements for the Development of Medicinal Products for Chronic Non\u2010Infectious Liver Diseases (PBC PSC NASH) \u201d(2018) https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/draft\u2010reflection\u2010paper\u2010regulatory\u2010requirements\u2010development\u2010medicinal\u2010products\u2010chronic\u2010non\u2010infectious\u2010liver\u2010diseases\u2010pbc\u2010psc\u2010nash_en.pdf."},{"key":"e_1_2_11_82_1","unstructured":"European Medicines A \u201cReflection Paper on Regulatory Requirements for the Development of Medicinal Products for Non\u2010Alcoholic Steatohepatitis (NASH) \u201d(2024) https:\/\/www.ema.europa.eu\/en\/documents\/scientific\u2010guideline\/reflection\u2010paper\u2010regulatory\u2010requirements\u2010development\u2010medicinal\u2010products\u2010non\u2010alcoholic\u2010steatohepatitis\u2010nash_en.pdf."},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32204"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591\u2010024\u201003301\u20102"},{"key":"e_1_2_11_85_1","unstructured":"Food US Drug A \u201cFDA Qualifies First AI Drug Development Tool Will Be Used in \u201cMASH\u201d Clinical Trials \u201d(2025) https:\/\/www.fda.gov\/drugs\/drug\u2010safety\u2010and\u2010availability\/fda\u2010qualifies\u2010first\u2010ai\u2010drug\u2010development\u2010tool\u2010will\u2010be\u2010used\u2010mash\u2010clinical\u2010trials."},{"key":"e_1_2_11_86_1","unstructured":"European Medicines A \u201cEMA Qualifies First Artificial Intelligence Tool to Diagnose Inflammatory Liver Disease (MASH) in Biopsy Samples \u201d(2025) https:\/\/www.ema.europa.eu\/en\/news\/ema\u2010qualifies\u2010first\u2010artificial\u2010intelligence\u2010tool\u2010diagnose\u2010inflammatory\u2010liver\u2010disease\u2010mash\u2010biopsy\u2010samples."},{"key":"e_1_2_11_87_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.05.033"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25084397"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26115164"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-025-10792-9"},{"key":"e_1_2_11_91_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2025.1513993"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl\u20102025\u2010337431"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.05.021"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI189953"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2025.12.015"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2020.06.045"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41575\u2010024\u201001031\u2010x"}],"container-title":["Liver International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70784","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/liv.70784","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/liv.70784","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T00:20:17Z","timestamp":1789172417000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/liv.70784"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,12]]},"references-count":96,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["10.1111\/liv.70784"],"URL":"https:\/\/doi.org\/10.1111\/liv.70784","archive":["Portico"],"relation":{},"ISSN":["1478-3223","1478-3231"],"issn-type":[{"value":"1478-3223","type":"print"},{"value":"1478-3231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,12]]},"assertion":[{"value":"2026-04-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70784"}}